Novavax Inc, a Biotech company announced today they have been awarded a $60M contract by the Defense Health Program, a subset of the U.S. Department of Defense, to develop a COVID-19 vaccine. Novavax is currently in production of NVX‑CoV2373, their current vaccine candidate, currently in Phase I/II development.
See our progress tracker where we track each manufacturer's progress on the COVID-19 vaccine.
As part of the contract, the vaccine will be manufactured in the U.S. with a targeted delivery of 10M doses some time in 2020. The vaccine could also be used under an "Emergency Use Authorization" (EUA) pending approval by the FDA or in Phase II/III clinical trials. Novovax will work with a U.S.-based biologics contract development manufacturing organization (CDMO) to scale up their supply chain and manufacture the antigens in the vaccines.
“We are genuinely honored at the opportunity to protect our military personnel and their families who have devoted themselves to the needs of U.S. citizens and others worldwide,” said Stanley C. Erck, President and Chief Executive Officer of Novavax. “Importantly, this award will allow Novavax to significantly expand its U.S. production capacity of NVX-CoV2373, a critical step in our ability to provide vaccine support to the COVID-19 pandemic.”
Novavax joins major manufacturers including AstraZeneca, who recently came in among four other finalists for the Trump administration's "Operation Warp Speed."